|
| 35263204 | A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma. | Leuk Lymphoma | 2023 |
| 37552126 | Cyclin-dependent kinase-9 in B-cell malignancies: pathogenic role and therapeutic implications. | Leuk Lymphoma | 2023 |
| 36993424 | Supervised learning of high-confidence phenotypic subpopulations from single-cell data. | bioRxiv | 2023 |
| 37420267 | T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia. | Mol Cancer Ther | 2023 |
| 37013954 | Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma. | Blood Adv | 2023 |
| 37173225 | Thinking "outside the germinal center": Re-educating T cells to combat follicular lymphoma. | Blood Rev | 2023 |
| 37067905 | METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL. | Blood Cancer Discov | 2023 |
| 37031300 | Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia. | Leukemia | 2023 |
| 36998071 | CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma. | Mol Cancer | 2023 |
| 37226703 | TRES, a validated three-factor comorbidity score, is associated with survival in older patients with mantle cell lymphoma. | Haematologica | 2023 |
| 36753602 | A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale. | Blood Adv | 2023 |
| 36516082 | Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia. | Blood Adv | 2023 |
| 36469551 | Generation of a humanized afucosylated BAFF-R antibody with broad activity against human B-cell malignancies. | Blood Adv | 2023 |
| 36735393 | A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma. | Blood Adv | 2023 |
| 36798339 | <i>MGA</i> deletion leads to Richter's transformation via modulation of mitochondrial OXPHOS. | bioRxiv | 2023 |
| 36631449 | Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. | Blood Cancer J | 2023 |
| 36754692 | SOHO State of the Art Updates and Next Questions: New Targetable Pathways in Chronic Lymphocytic Leukemia. | Clin Lymphoma Myeloma Leuk | 2023 |
| 36094847 | Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL. | Blood Adv | 2023 |
| 34196037 | Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia. | Br J Clin Pharmacol | 2022 |
| 35700381 | Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. | Blood | 2022 |
| 35831896 | A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells. | Exp Hematol Oncol | 2022 |
| 35855508 | Current status of phosphoinotiside-3 kinase inhibitors in blood cancers. | Curr Opin Oncol | 2022 |
| 35420395 | CAR T-Cell Therapy in the Older Person: Indications and Risks. | Curr Oncol Rep | 2022 |
| 35389445 | Immunity in CLL: corrupt at inception? | Blood | 2022 |
| 36467840 | A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. | EJHaem | 2022 |
| 35868306 | Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. | Cancer Cell | 2022 |
| 35901825 | PI3K inhibitors in haematological malignancies. | Lancet Oncol | 2022 |
| 36125953 | Clinical use of measurable residual disease in CLL. | Clin Adv Hematol Oncol | 2022 |
| 35914220 | Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma. | Blood | 2022 |
| 35008098 | The CLL comorbidity index in a population-based cohort: a tool for clinical care and research. | Blood Adv | 2022 |
| 34882582 | Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. | J Clin Invest | 2022 |
| 35305092 | Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment. | Oncologist | 2022 |
| 35296646 | Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma. | Cell Death Dis | 2022 |
| 34674981 | Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine. | Clin Lymphoma Myeloma Leuk | 2022 |
| 34764492 | Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data. | Nat Biotechnol | 2022 |
| 32203139 | Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells. | Leukemia | 2021 |
| 33796237 | The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia. | Ther Adv Hematol | 2021 |
| 33683501 | A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. | Invest New Drugs | 2021 |
| 33538152 | Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. | Haematologica | 2021 |
| 33507515 | High-Risk Mantle Cell Lymphoma in the Era of Novel Agents. | Curr Hematol Malig Rep | 2021 |
| 33504141 | Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies. | Haematologica | 2021 |
| 33502927 | Burkitt Lymphoma International Prognostic Index. | J Clin Oncol | 2021 |
| 33499685 | Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy. | Expert Rev Anticancer Ther | 2021 |
| 34676055 | Neddylation and anti-tumor immunity. | Oncotarget | 2021 |
| 34611480 | NEDD8-activating enzyme inhibition induces cell cycle arrest and anaphase catastrophe in malignant T-cells. | Oncotarget | 2021 |
| 34516611 | Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. | Blood Adv | 2021 |
| 34324220 | Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. | Am J Hematol | 2021 |
| 34233959 | Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a <i>TP53-</i> and <i>BAX-</i>Dependent Manner. | Clin Cancer Res | 2021 |
| 34283175 | HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. | Blood Adv | 2021 |
| 34168050 | The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. | Clin Cancer Res | 2021 |